Teemu T. Junttila - Concepedia

Author

Teemu T. Junttila

Also Known As

Klara Totpal, T Junttila, T. Junttila, T. T. Junttila, T.T. Junttila, Teemu Junttila, Teemu T Junttila, Teemu T. Junttila, Teemu T. Junttila

100

Publications

5.4K

Citations

H-Index

Concepts

All Affiliations

University of Turku Turku University Hospital Tampere University Hospital University of Helsinki

About

Teemu T. Junttila is an author at University of Turku specializing in medicine, cell biology, and tumor biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	12	12	2.9K
2	Cell Biology	11	11	2.2K
3	Immunology	5	5	1.1K
4	Cellular Physiology	2	2	162
5	Health Sciences	1	1	53

Teemu T. Junttila

Publications

5.1K

Citations

H-Index

Page 1

	Year	Citations
Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941 Teemu T. Junttila, Robert W. Akita, Kathryn L. Parsons, Cancer Cell Molecular PharmacologySignaling PathwayMedicineReceptor Tyrosine KinasePharmacotherapy	2009	822
Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIα gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab Minna Tanner, Maija Hollmén, Teemu T. Junttila, Annals of Oncology Intestinal TypeOncologyGastrointestinal OncologyMedicinePathology	2005	656
Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer Teemu T. Junttila, Guangmin Li, Kathryn L. Parsons, Breast Cancer Research and Treatment Breast OncologyOncologyMedicineImmunologyImmune Checkpoint Inhibitor	2010	523
Membrane-Proximal Epitope Facilitates Efficient T Cell Synapse Formation by Anti-FcRH5/CD3 and Is a Requirement for Myeloma Cell Killing Ji Li, Nicola J. Stagg, Jennifer Johnston, Cancer Cell Synapse FormationImmunologyImmunoeditingCell DeathImmunologic Mechanism	2017	289
Anti-CD20/CD3 T cell–dependent bispecific antibody for the treatment of B cell malignancies Liping Sun, Diego Ellerman, Mary Mathieu, Science Translational Medicine	2015	269
Characterization of a novel cell line established from a patient with Herceptin-resistant breast cancer Minna Tanner, Anita I. Kapanen, Teemu T. Junttila, Molecular Cancer Therapeutics Tumor BiologyBreast OncologyNovel Cell LineClinical ResistanceHerceptin-resistant Breast Cancer	2004	267
Signaling via ErbB2 and ErbB3 Associates with Resistance and <i>Epidermal Growth Factor Receptor</i> (<i>EGFR</i>) Amplification with Sensitivity to EGFR Inhibitor Gefitinib in Head and Neck Squamous Cell Carcinoma Cells Kaisa Erjala, Maria Sundvall, Teemu T. Junttila, Clinical Cancer Research	2006	255
Superior <i>In vivo</i> Efficacy of Afucosylated Trastuzumab in the Treatment of HER2-Amplified Breast Cancer Teemu T. Junttila, Kathryn L. Parsons, Christine Olsson, Cancer Research	2010	216
Cleavable ErbB4 Isoform in Estrogen Receptor–Regulated Growth of Breast Cancer Cells Teemu T. Junttila, Maria Sundvall, Mikael Lundin, Cancer Research	2005	188
ERBB receptor signaling promotes ependymoma cell proliferation and represents a potential novel therapeutic target for this disease. Richard J. Gilbertson, Lyndsay Bentley, Roberto Hernán, PubMed	2002	186

Page 1